Poor
Not Aligned
Patient Risk:
High
Summary
Multiple statements attribute erectile dysfunction (ED) use, side effects, and patient reports to ALYQ (tadalafil) when the provided FDA label excerpts are for ALYQ in pulmonary arterial hypertension (PAH). The response also includes drug-class/half-life/sustained-effect and prescription-access/patent-protection claims that are not supported by the provided label excerpts, and it does not address key on-label contraindications (nitrates/GC stimulators) or PAH-specific administration/dosing constraints.
Category Scores
Accurate Statements
Hims Tadalafil is part of the class of ED medications known as phosphodiesterase-5 (PDE5) inhibitors.
Unsupported for ED-specific framing based on provided label excerpt; however, label excerpt states tadalafil is a PDE5 inhibitor (SECTION 12.1: “Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5)…”).
Unsupported Statements
Hims Tadalafil is a medication used to treat erectile dysfunction (ED).
Provided label excerpts for ALYQ specify indication for pulmonary arterial hypertension (PAH) (SECTION 1.1). No provided excerpt supports ED use for ALYQ.
Hims Tadalafil has been linked to common side effects including headaches, dizziness, diarrhea, and stomach upset.
The provided excerpts do not list these specific adverse events as common AEs (SECTION 6.1 only references Table 1 without providing the listed AE terms).
Hims Tadalafil may cause less common side effects including back pain, muscle pain, and flushing.
The provided excerpts do not provide support for these specific adverse events or frequency descriptors.
Hims Tadalafil has a longer half-life than other PDE5 inhibitors such as sildenafil (Viagra) and vardenafil (Levitra).
No half-life comparison statements are included in the provided label excerpts.
Because Hims Tadalafil has a longer half-life, it can last longer in the body and provide sustained effects.
Not supported by the provided label excerpts.
Some patients report improved erectile function with Hims Tadalafil.
Not supported; provided ALYQ label excerpt is PAH-indication (SECTION 1.1) and does not address ED outcome reporting.
Some patients report a boost in confidence with Hims Tadalafil.
Not supported by provided label excerpts.
Some patients have concerns about the cost and efficacy of Hims Tadalafil.
Not supported by provided label excerpts.
Hims Tadalafil is available only through prescription from a licensed healthcare professional.
Not addressed in provided label excerpts.
Hims Tadalafil has potential side effects and interactions with other medications.
While interactions/precautions exist in the label, the statement is too general and not directly supported by provided excerpts as written; it is not a precise on-label interaction statement.
There are alternative ED medications available including sildenafil, vardenafil, and avanafil (Stendra).
Not supported in provided label excerpts (and framed as ED alternatives, which is not supported for ALYQ by the provided indication excerpt).
Because Hims Tadalafil is a prescription medication, it is subject to patent protection.
Not addressed by provided label excerpts.
Contradictions
High
AI Statement
Hims Tadalafil is a medication used to treat erectile dysfunction (ED).
Label Reference
SECTION 1.1 indicates ALYQ is indicated for treatment of pulmonary arterial hypertension (PAH), not ED (provided excerpts).
Important Omissions
ALYQ contraindication to organic nitrates and timing restriction (do not use nitrates within 48 hours of last dose).
Importance:
High
ALYQ contraindication with guanylate cyclase (GC) stimulators such as riociguat.
Importance:
High
Key warnings/precautions relevant to safety in ALYQ label excerpt (e.g., hypotension/vasodilatory effects, PVOD worsening not recommended, NAION visual loss warning, sudden hearing loss warning, priapism/prolonged erection emergency).
Importance:
High
On-label dosing: recommended 40 mg once daily; do not divide dose.
Importance:
Moderate
Renal/hepatic dose adjustments and avoidance in severe impairment per label excerpts.
Importance:
Moderate
Interaction instruction: do not take other PDE5 inhibitors with ALYQ (not studied; inform patients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response misstates the on-label indication as erectile dysfunction, and omits major contraindications and key warnings (nitrates/GC stimulators, hypotension/PVOD/NAION/hearing loss/priapism). This could lead to unsafe use or misunderstanding of ALYQ prescribing requirements based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Indication mismatch (ED vs on-label PAH) plus multiple unsupported or non-label claims and omission of major contraindications/warnings.
Suggested Improvement
Limit claims to the provided ALYQ label excerpts: describe ALYQ indicated for PAH and include key contraindications (nitrates within 48 hours; GC stimulators), major warnings/precautions (hypotension, PVOD, NAION/visual loss, sudden hearing loss, prolonged erection/priapism), and avoid unsupported ED and half-life/sustained-effect statements unless explicitly supported by the label.